CD28 and neoplasm: Local intracranial delivery of HER2 CAR T cells with either a 4-1BB or CD28 costimulatory domain eliminated brain metastases and extended survival past 100 days post tumor implantation, whereas control mice did not survive past 35 days of treatment.